Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC
Martin Schuler, James Chih-Hsin Yang, Lecia V. Sequist, Yi-Long Wu, Caicun Zhou, Sarayut L Geater, Tony Mok, Eng-Huat Tan, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Vera Hirsh, Yunchao Huang, Stuart Ellis, Carl Samuelsen, Angela Märten, Jean Fan, Keunchil Park, Luis Paz-Ares
Learn more about the science behind this poster in the videos, papers and other materials below.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue